JP7849141B2 - がんの治療のためのｎｏｘ阻害剤の使用 - Google Patents

がんの治療のためのｎｏｘ阻害剤の使用

Info

Publication number
JP7849141B2
JP7849141B2 JP2020544112A JP2020544112A JP7849141B2 JP 7849141 B2 JP7849141 B2 JP 7849141B2 JP 2020544112 A JP2020544112 A JP 2020544112A JP 2020544112 A JP2020544112 A JP 2020544112A JP 7849141 B2 JP7849141 B2 JP 7849141B2
Authority
JP
Japan
Prior art keywords
cancer
optionally substituted
inhibitor
nox4
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501216A5 (https=
JP2021501216A (ja
Inventor
フィリップ・ヴィセル
フレディ・ハイツ
ギャレス・トーマス
クリストファー・ハンリー
カースティ・フォード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Publication of JP2021501216A publication Critical patent/JP2021501216A/ja
Publication of JP2021501216A5 publication Critical patent/JP2021501216A5/ja
Priority to JP2023131209A priority Critical patent/JP2023162250A/ja
Application granted granted Critical
Publication of JP7849141B2 publication Critical patent/JP7849141B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020544112A 2017-11-01 2018-11-01 がんの治療のためのｎｏｘ阻害剤の使用 Active JP7849141B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023131209A JP2023162250A (ja) 2017-11-01 2023-08-10 がんの治療のためのｎｏｘ阻害剤の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17199601.0A EP3479843A1 (en) 2017-11-01 2017-11-01 Use of nox inhibitors for treatment of cancer
EP17199601.0 2017-11-01
PCT/EP2018/079945 WO2019086579A1 (en) 2017-11-01 2018-11-01 Use of nox inhibitors for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023131209A Division JP2023162250A (ja) 2017-11-01 2023-08-10 がんの治療のためのｎｏｘ阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2021501216A JP2021501216A (ja) 2021-01-14
JP2021501216A5 JP2021501216A5 (https=) 2021-12-16
JP7849141B2 true JP7849141B2 (ja) 2026-04-21

Family

ID=60201917

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544112A Active JP7849141B2 (ja) 2017-11-01 2018-11-01 がんの治療のためのｎｏｘ阻害剤の使用
JP2023131209A Pending JP2023162250A (ja) 2017-11-01 2023-08-10 がんの治療のためのｎｏｘ阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023131209A Pending JP2023162250A (ja) 2017-11-01 2023-08-10 がんの治療のためのｎｏｘ阻害剤の使用

Country Status (15)

Country Link
US (2) US12011436B2 (https=)
EP (2) EP3479843A1 (https=)
JP (2) JP7849141B2 (https=)
KR (2) KR20200079265A (https=)
CN (1) CN111344013A (https=)
AU (1) AU2018359634B2 (https=)
BR (1) BR112020008440A2 (https=)
CA (1) CA3079991A1 (https=)
DK (1) DK3703747T3 (https=)
ES (1) ES3054839T3 (https=)
FI (1) FI3703747T3 (https=)
IL (1) IL274198B2 (https=)
MX (1) MX2020004376A (https=)
PT (1) PT3703747T (https=)
WO (1) WO2019086579A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
US12377117B2 (en) 2019-04-01 2025-08-05 Emory University Hyaluronic acid nanoparticles comprising NADPH oxidases inhibitors and uses in treating cancer
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
CN119096936A (zh) * 2024-08-28 2024-12-10 南方医科大学第三附属医院（广东省骨科研究院） 一种胆管癌足垫腘窝淋巴结自发转移动物模型的构建方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931407A (en) 1973-03-01 1976-01-06 American Hoechst Corporation Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent
DE3728278A1 (de) 1986-12-17 1988-06-23 Bayer Ag Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
EP1291017A3 (en) 2001-09-10 2003-07-02 Warner-Lambert Company Use of statins to inhibit formation of osteoclasts
EP1505068A4 (en) 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND INHIBITOR OF NAD (P) H OXIDASE CONTAINING SAID DERIVATIVE
JP2006520326A (ja) 2003-02-28 2006-09-07 ハワード フローリー インスティチュート オブ エクスペリメンタル フィジオロジー アンド メディシン 治療薬
JPWO2004089412A1 (ja) 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的ｎａｄ（ｐ）ｈオキシダーゼ抑制剤
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
AU2005294404A1 (en) 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for Alzheimer's disease
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US20070014739A1 (en) 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
DE102005048897A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
CA2648652A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
AU2007292302A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
PL2091530T3 (pl) 2006-11-13 2018-01-31 Pcb Ass Inc Kompozycja hamująca aktywność oksydazy nadph
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2000176A1 (en) 2007-06-04 2008-12-10 GenKyo Tex Tetrahydroindole derivatives as NADPH Oxidase inhibitors
TW200930713A (en) 2007-12-03 2009-07-16 Takeda Pharmaceutical Nitrogen-containing heterocyclic compound and use thereof
US20090163452A1 (en) 2007-12-20 2009-06-25 Schwartz Janice B Compositions and methods for lowering serum cholesterol
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2305679A1 (en) * 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
CA2823974A1 (en) 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
EP2361912A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
WO2012150543A1 (en) 2011-05-02 2012-11-08 Universite De Geneve Macrocyclic lactones and use thereof
EP2591782A1 (en) * 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
EP2857399A1 (en) 2013-10-03 2015-04-08 GenKyoTex SA Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
US10584118B2 (en) 2015-06-22 2020-03-10 Actelion Pharmaceuticals Ltd NADPH oxidase 4 inhibitors

Also Published As

Publication number Publication date
DK3703747T3 (en) 2025-12-01
MX2020004376A (es) 2020-12-03
CN111344013A (zh) 2020-06-26
IL274198B2 (en) 2023-07-01
AU2018359634A1 (en) 2020-05-21
WO2019086579A1 (en) 2019-05-09
JP2023162250A (ja) 2023-11-08
BR112020008440A2 (pt) 2020-10-06
RU2020115807A3 (https=) 2022-02-16
US20210177811A1 (en) 2021-06-17
IL274198A (en) 2020-05-31
US12011436B2 (en) 2024-06-18
FI3703747T3 (fi) 2025-12-04
PT3703747T (pt) 2025-12-05
RU2020115807A (ru) 2021-11-15
ES3054839T3 (en) 2026-02-06
US20240358687A1 (en) 2024-10-31
JP2021501216A (ja) 2021-01-14
EP3703747B1 (en) 2025-09-03
CA3079991A1 (en) 2019-05-09
KR20250086790A (ko) 2025-06-13
IL274198B1 (en) 2023-03-01
KR20200079265A (ko) 2020-07-02
AU2018359634B2 (en) 2025-07-24
EP3703747A1 (en) 2020-09-09
EP3479843A1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
JP7849141B2 (ja) がんの治療のためのｎｏｘ阻害剤の使用
US20200113896A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
JP2022043060A (ja) 組み合わせ治療
JP2021046415A (ja) 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
JP2020169223A (ja) 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
US20120128670A1 (en) mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
JPWO2008111441A1 (ja) 医薬組成物
KR20230059792A (ko) 암 치료를 위한 조합
CN101820915A (zh) 用于治疗癌症的方法和组合物
US20170355768A1 (en) Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
RU2780354C2 (ru) Применение ингибиторов nox для лечения рака
RU2780354C9 (ru) Применение ингибиторов nox для лечения рака
JP2026500719A (ja) アルファ－ｖ－ベータ－８インテグリン阻害剤及びその使用
KR20250129099A (ko) 암 면역요법-관련 사이토카인 방출 증후군 완화를 위한 의약품 및 방법
US20240141436A1 (en) Compounds, Compositions and Methods of Treatment Thereof
HK40103680A (zh) 化合物、组合物及其治疗方法
CN117098537A (zh) 用于癌症治疗的联合疗法
JP2022540317A (ja) Ｈｓｐ９０結合コンジュゲートおよびその併用療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230817

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230906

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260409